MICHAEL JONES: Open Payments
NPI 1972523991 · MEXICO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$553 in 34 payments from 8 companies in 2025. Trend: 2023 $659 · 2024 $477 · 2025 $553
Food & beverage: $553
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $177 |
| Neurocrine BioSciences, Inc. | 9 | $138 |
| ABBVIE INC. | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Corcept Therapeutics | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: CAPLYTA, INGREZZA, VRAYLAR, FANAPT, AUSTEDO XR, Auvelity, Korlym, REXULTI.
Industry payments across MO — which companies pay providers there.
